Due to the limited sample size in NIT subgroup, we might overstate the clinical effect and survival benefit of NIT, which might be ascribed to the imbalance in the rate of patients with KIT exon 17 mutation between NIT and IST and might partly explain the contradiction on the role of venetoclax-based regimen in KIT mut AML between our study and the previous study [28]. The gene discussed is KIT; the disease is acute myeloid leukemia.